Introduction
Breast cancer is the most common cancer and the most common cause of cancer-related death in women. 1 Despite earlier diagnosis and improvement in adjuvant therapies, approximately 20%-40% of the patients initially diagnosed with earlier stages of breast cancer eventually develop recurrent or metastatic disease. [2] [3] [4] Despite various treatments used in patients with metastatic breast cancer (MBC), the best 5-year relative overall survival (OS) rate is only 20%, 5 and the median OS time is 2 to 3 years. 6 Therefore, treatments that provide clinical benefit among these patients will continue to be sought.
Taxanes, such as solvent-based paclitaxel (sb-paclitaxel) and docetaxel, are considered one standard of care for patients with breast cancer. However, these drugs are highly hydrophobic and need synthetic solvents to enable parenteral administration. Paclitaxel contains a combination of polyethylated castor oil (Cremophor EL; BASF, Ludwigshafen, Germany) and ethanol as the vehicle; polysorbate 80 and an ethanol
Dovepress

1444
sun et al diluent are the vehicles for docetaxel. These solvents directly contribute to severe hypersensitivity reactions and myelosuppression observed in patients treated with paclitaxel or docetaxel, even with corticosteroid premedication.
Nab-paclitaxel (Abraxane ® for injectable suspension; Abraxis BioScience, Los Angeles, CA, USA), an albuminbound 130 nm particle form of paclitaxel, was developed to avoid toxicities associated with the Cremophor vehicle in sbpaclitaxel. [7] [8] [9] [10] Preclinical data in animals have demonstrated increased antitumor activity of nab-paclitaxel compared with equitoxic doses of sb-paclitaxel. 11 These findings were confirmed clinically, and nab-paclitaxel consistently demonstrates superior efficacy compared with sb-paclitaxel. In a phase III trial, nab-paclitaxel showed a significantly higher overall response rate (ORR), a longer time to progression (TTP), and greater OS in patients treated with second-line or greater therapy compared with patients who received sb-paclitaxel. 8 Furthermore, weekly nab-paclitaxel can be safely administered at doses exceeding those typically used for sb-paclitaxel, 12 is effective in taxane resistant patients, 13 and as a single drug is more effective than docetaxel, which was previously considered the most potent drug for MBC.
14 Therefore, weekly nabpaclitaxel is becoming a standard of care for MBC patients.
To further improve the efficacy of weekly nab-paclitaxel in MBC patients, several studies tested combinations by adding other chemotherapeutic agents or biologicals. In the current Phase II study, conducted in the Department of Medical Oncology, Fudan University Shanghai Cancer Center, People's Republic of China, we assessed the efficacy and safety of combination of nab-paclitaxel and cisplatin in patients with MBC.
Patients and methods Patients
Women older than 18 years with pathologically confirmed unresectable stage IV breast cancer, measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, 15 as well as an Eastern Cooperative Oncology Group performance status of 0-2, 16 were eligible for inclusion. Therapy with a taxane as part of adjuvant or neoadjuvant therapy was allowed but should have been completed at least 12 months before study entry. Prior taxanes in the metastatic setting were also permitted if they were completed at least 3 months before study enrolment.
Patients were excluded if they had clinical evidence of brain metastasis or clinically serious concurrent diseases, preexisting peripheral neuropathy higher than grade 1, concurrent hormonal therapy or immunotherapy, or other malignancy within the last 5 years that could affect the diagnosis or assessment of breast cancer.
The trial was approved by the Ethics Committee of Fudan University Shanghai Cancer Center and carried out in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent before any study-related procedure (ClinicalTrials.gov identifier: NCT01149798). 17 
Treatment
Eligible patients received treatment every 4 weeks with a combination of nab-paclitaxel and cisplatin. Nab-paclitaxel was administered at a dose of 125 mg/m 2 , over 30 minutes, on days 1, 8, and 15, without corticosteroid or antihistamine premedication or special infusion sets. Cisplatin was given at a dose of 75 mg/m 2 on day 1 with hydration for 3 continuous days. The treatment continued until disease progression, intolerable toxicities, or a maximum of six cycles. If grade 4 neutropenia occurred over the course of more than 7 days or febrile neutropenia occurred, the patients continued the next cycle at a reduced dose after the hematologic toxicity recovered to grade 1 or less. If grade 3/4 nonhematologic toxicities except nausea/vomiting occurred, the patients withheld the treatment until the toxicity recovered to grade 2 or lower and then continued at the lowered dose. Treatment could be delayed up to 14 days to allow sufficient time for recovery from hematologic or nonhematologic toxicities. Treatment was permanently discontinued if dose modification of more than double was required, with a 20%-25% reduction each time.
assessments Pretreatment evaluation included a complete medical history and physical examination, hematological and biochemical profiles, carcinoembryonic antigen and cancer antigen 15-3, electrocardiography, bone scan (if clinically indicated), computerized tomography of the chest, and magnetic resonance imaging of the abdomen. During treatment, complete blood counts were performed weekly, or every 2 days in the case of grade 3/4 neutropenia or thrombocytopenia, until hematologic recovery.
The primary endpoint of this study was investigatorassessed ORR, and the secondary endpoints were progressionfree survival (PFS), OS, and safety. Efficacy was evaluated in patients who received at least 2 cycles of chemotherapy. All patients were assessed for tumor response every 8 weeks by clinical examination and radiographic assessments (computed tomography or magnetic resonance imaging).
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Weekly nab-paclitaxel and cisplatin in MBc Disease status was assessed by investigators according to RECIST 1.1. All radiographic images were copied and provided to the independent radiologists and reviewed in a blinded fashion following the RECIST 1.1 criteria. Complete response (CR) was defined as the disappearance of all known lesions and the normalization of tumor marker level for at least 4 weeks. Partial response (PR) was defined as a reduction of the sum of all measurable lesions by at least 30% for at least 4 weeks. Progressive disease was defined as an increase of the sum of all measurable lesions by greater than 20% or the appearance of a new lesion, and stable disease was defined as neither CR and PR nor progressive disease. ORR was defined as the sum of CR and PR rates. In patients with tumor response or stable disease, treatment was planned to be continued for up to 6 cycles; thereafter, maintenance therapy was not recommended but could be started at the clinician's decision. After completion of the treatment period, the patients were followed-up every 3 months.
All toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) 4.0. 18 
statistical analysis
Sample size was calculated on the basis of Simon's two-stage Phase II clinical trial design. 19 The ORR of combination was hypothesized as 60% with the addition of cisplatin in the whole population compared with 40% for nab-paclitaxel monotherapy, as reported in published studies. 13, 14 The design had 90% power with a type 1 error of α=0.05. If 11 of the first 25 patients enrolled achieved CR or PR, the study moved to the second stage, and if there were 32 patients responding of 66 total patients assessed by investigators and the results were confirmed by an independent review, the study was positive to prove the hypothesis. The sample size was calculated as 72, including a 10% dropout rate.
All statistical analyses were carried out on SPSS 20.0 software (IBM Corporation, Armonk, NY, USA). PFS was calculated for all intention-to-treat patients as the time from inclusion to disease progression or death from any cause. OS was calculated for all patients from the date of inclusion until death. The PFS and OS were computed using the Kaplan-Meier method. The statistical difference was considered significant if the P-value was less than 0.05.
Results
Patients
A total of 73 patients were enrolled into this study starting in June 2010, and all received at least a single injection of the study drug and were evaluated for efficacy and safety. The patient characteristics are listed in Table 1 . The median age of patients was 49 years (range, 33-65 years). The majority of patients (93.2%) relapsed after primary radical surgery for breast cancer; only 5 patients (6.8%) initially presented with de novo stage IV diseases. Thirty-four patients (46.6%) had involvement of more than three metastatic sites, and 59 patients (80.8%) had visceral diseases. Nearly half of the patients (49.3%) were chemonaïve for metastatic diseases, whereas 28 (38.4%) and 9 (12.4%) patients received chemotherapy as second-line and third-line therapy or beyond, respectively. Table 3 . The efficacy results were quite similar, with no significant difference between investigator and independent radiology reviews.
PFs and Os
After the median follow-up of 26.3 months, 37 patients (50.7%) died; the median OS (mOS) was 26.9 months ( Figure  1A ). The patients not pretreated with taxanes showed longer median OS (not reached) compared with those pretreated with taxanes (16.7 months; P<0.001; Figure 1B ). Sixty-six patients (90.4%) had disease progression or death, among whom one died of non-breast-cancer related causes. The median PFS (mPFS) was 9.8 months (95% confidence interval [CI], 8.1-11.6 months) by investigator assessment and 9.3 months (95% CI, 7.6-11.0 months) by independent assessment (Figure 2A and B). By both investigator and independent assessment, median PFS decreased significantly with the successive chemotherapy regimen. For the patients receiving first-, second-, and third-line therapy or beyond, median PFS was 11.7, 7.7, and 7.6 months, respectively (P=0.005) by investigator assessment and, correspondingly, 11.7, 6.6, and 7.6 months, respectively, by independent review (P=0.006; Figure 2C and D). The longer PFS was also seen in patients not treated with taxanes previously. Median PFS for patients with and without prior taxanes was 8.5 and 11.2 months, respectively (P=0.009), by investigator assessment, and correspondingly, 7.6 and 11.2 months, respectively, by independent review (P=0.009; Figure 2E and F).
Molecular subtype analysis
Molecular subtyping in our data was based on an analysis of the primary tumor, not the recurrent or metastatic lesion. Seventy patients (95.9%) with the molecular subtype information available were divided into three subgroups: luminal type (n=46, 63.0%), human epidermal growth factor receptor 2 (HER2)-positive type (n=8, 11.0%), and triple-negative type (n=16, 21.9%). The results of immunohistochemistry (IHC) tests were not available in the other three patients (4.1%). Subgroup analysis showed that objective response among the three subtypes was not statistically significant by investigator assessment (P=0.912), as well as independent radiology assessment (P=0.070). The PFS was not significant among the three subtype groups (P=0.323 by investigator assessment; P=0.301 by independent radiology assessment). Table 4 . The most common and severe treatment-related hematologic AEs were grade 3/4 neutropenia and leukopenia, which occurred in 62 (84.9%) and 54 (75.3%) patients, respectively. Grade 4 neutropenia occurred in 46 patients (63.0%), whereas febrile neutropenia occurred in 9 patients (12.3%). There were 27 patients (37.0%) who received dose reductions because of hematologic toxicity, among whom 5 patients (6.8%) experienced dose adjustment twice.
Grade 3 peripheral neuropathy was an accumulated doselimiting toxicity occurring in 19 patients (26.0%), among whom 13 had to stop chemotherapy as a result of no recovery to grade 2 or less, even with an allowance of 2 weeks' delay as per protocol. However, all patients recovered to grade 2 or less neurotoxicity within 3 months after treatment stopped, whereas only one patient still experienced grade 2 sensory neurotoxicity 1 year after the last dose.
Skin rash was reported by Tang et al in BMC cancer. 20 It is another common toxicity mainly caused by nabpaclitaxel and present in 27 patients (37.0%). The most common sites involved were face (14/27), neck (14/27), limbs (18/27), and frictional parts of the trunk (10/27). Macular and papular rash with pruritus commonly occurred 2 (range, 1-7) days after the first day of chemotherapy. Only one patient developed grade 3 skin toxicity with generalized erythroderma and disfigurement of the face requiring dose reduction. The rash gradually regressed 2 (range, 1-10) days after using antihistamines, and pigmentation remained in 13/27 cases. The incidence rate of skin rash was significantly different between Chinese and Western patients. 21 Other common toxicities of all grades included alopecia (100%), nausea (64.4%), vomiting (61.6%), and fatigue (34.2%). Most of these AEs were not severe and could be 
Discussion
To our knowledge, this is the first prospective study to investigate the efficacy and toxicity of weekly nab-paclitaxel and cisplatin combination in breast cancer. The rationale for this novel regimen is based on single-agent activity and synergism of the two drugs. Weekly nab-paclitaxel has been regarded as the most effective monotherapy in breast cancer. 14 A synergistic effect is present between taxanes and platinum salts (cisplatin and carboplatin) in human breast cancer and other solid tumors, motivating us to test the combination of the two drugs. 22 Several trials adding other drugs to nab-paclitaxel have been conducted to further improve the efficacy, such as carboplatin, gemcitabine, bevacizumab, and herceptin. [23] [24] [25] On the basis of our knowledge, this is also the first trial showing that the already-strong antitumor activity of weekly nab-paclitaxel for MBC can be further increased by adding a chemotherapeutic agent.
Our results demonstrated an investigator-assessed ORR of 67.1% in patients with MBC, which was further validated by an independent radiology review and met its primary endpoint with 60% of ORR for the whole population. Taxanes, such as paclitaxel and docetaxel, are a cornerstone of treatment for MBC patients, especially considering the fact that many patients with recurrent disease already have had substantial anthracycline exposure in the neoadjuvant and/or adjuvant International Journal of Nanomedicine 2014:9
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Weekly nab-paclitaxel and cisplatin in MBc setting, and rechallenging anthracyclines is generally avoided. More important, this regimen provided a quick response. A large percentage of patients (83.7%) experienced quick, remarkable tumor shrinkage with only two cycles of chemotherapy, which was quicker than the reported regimens, such as capecitabine/docetaxel, which showed a majority of all responses (75.5%) occurring in the first four treatment cycles. 26 Therefore, this doublet using a dose-dense new formulation of paclitaxel should be further explored to meet the unmet needs of MBC patients.
This new combination regimen had excellent efficacy in term of PFS and OS, as well as ORR, when compared with other taxane-based regimens (even the combination of taxane and molecular targeting agents in patients with MBC; Table 5 ). [26] [27] [28] [29] [30] [31] In the 36 patients who received the chemotherapy as the first-line treatment, ORR was as high as 80.6%. In MBC patients receiving chemotherapy only, longer PFS and OS with this doublet were noted when compared with capecitabine/ docetaxel 26 or gemcitabine/paclitaxel. 27 This regimen should be therefore compared with standard strategies for the treatment of MBC. It should also be explored in the neoadjuvant setting because higher and quicker objective responses are more desired there. Even as second-and third-line or more treatments, this regimen still had substantial antitumor activity, with ORRs of 57.1% and 44.4%, respectively, which is higher than reported in the literature. 32 Therefore, our data present a strong rationale for its use throughout the disease course.
An analysis of our data showed that this doublet is effective in patients pretreated with taxanes. As reported by Guo et al, rechallenging taxane as first-and later-line treatment for patients with recurrent disease after (neo-)adjuvant taxanebased therapy yielded response rates of 48.6% and 28.2%, respectively, which was considered by the authors as a reasonable option. 33 In our study, more than half of the patients (58.9%) had been pretreated with taxanes, among whom 12 patients (16.4%) were exposed to taxanes in the metastatic setting. The subgroup analysis of our data showed 58.1% of ORRs in taxane-exposed patients, which further validates the strong antitumor activities of this novel regimen.
It is always an interesting topic whether efficacy of chemotherapeutic agent is related to any specific molecular subtype of breast cancer. A recent meta-analysis from Early Breast Cancer Trialists' Collaborative Group showed that both anthracycline and taxane can provide benefit in patients with early breast cancer, regardless of estrogen receptor status, indicating that chemotherapy benefit is not limited to any specific molecular subtype of breast cancer. 34 Our results showed there was no significant association of ORR or PFS with luminal type or HER2-positive or triple-negative breast cancer, indicating that the doublet might be equally effective across these molecular subtypes.
As a novel generation compound, nab-paclitaxel in combination with cisplatin has been shown to improve efficacy, and it is natural to question whether there will be additive toxicity. The most frequently reported grade 3/4 AEs of weekly nab-paclitaxel (150 mg/m 2 ) alone included neutropenia (44%) and sensory neuropathy (14%).
14 In our study, the combination increased the grade 3/4 neutropenia and neurotoxicity to 84.9% and 26%, respectively. However, neutropenia was clinically manageable with the use of granulocyte colony-stimulating factors and dose-adjustment. Neurotoxicity is another concern of the combined regimen. In our study, all grades of peripheral neurotoxicity occurred Among them, 13 patients with grade 3 peripheral neurotoxicity who showed no recovery to grade 2 or less had to stop chemotherapy, as our protocol allowed delay of chemotherapy for no more than 2 weeks. Gradishar et al reported that the median recovery time to grade 2 or less for nab-paclitaxelinduced neurotoxicity was about 22 days. 8 Further follow-up of our patients showed that most of the neuropathy was sensory neuropathy, and all patients could recover to grade 2 or less within 3 months after the last dose, whereas only a single patient still experienced grade 2 toxicity 1 year after. Therefore, further assessment of neurotoxicity of this doublet should be also done in the future Phase III trial.
This trial should be also interpreted within the context of trials of weekly nab-paclitaxel-based therapy in MBC patients. 24, 35, 36 It remains a question whether we can improve efficacy of weekly nab-paclitaxel by combining other antitumor agents. The combination with trastuzumab proves to be a reasonable option, with ORRs and median PFS ranging from 52.4% to 62.5%, and from 16.6 to 18.7 months, respectively. 24, 36 Weekly use of nab-paclitaxel/bevacizumab was promising in a Phase II trial; 35 however, a subsequent large Phase III trial reported by Rugo et al did not show any more benefits than a weekly paclitaxel/bevacizumab doublet. 37 In combination with other chemotherapeutic agents, a weekly nab-paclitaxel-based combination has never been reported to be successful in MBC to our knowledge. A recent Phase III trial demonstrated that weekly use of the doublet of nab-paclitaxel/carboplatin is promising in non-small-cell lung cancer patients. 38 Our study first demonstrates that in the management of MBC patients, the efficacy of weekly nab-paclitaxel can be improved by adding cisplatin.
Conclusion
The results of this trial add to the clinical evidence that the combination of weekly nab-paclitaxel and cisplatin has high efficacy, quick response, and manageable toxicity in MBC. This doublet might be equally effective against luminal breast cancer as well as HER2-positive and triple-negative breast cancer. A further Phase III trial is warranted. 
